Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment

Next Previous
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Canagliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors Janssen Research & Development; Janssen-Cilag

    • Most Recent Events

    • 21 Jan 2022 This trial has been completed in Latvia, according to European Clinical Trials Database record (2 Aug 2012)
    • 29 Jun 2021 Results (n=14543)pooled hispanic subgroup analysis from the CANVAS Program and CREDENCE assessing effects of canagliflozin (CANA) on major adverse cardiovascular events (MACE) by baseline EGFR presented at the 81st Annual Scientific Sessions of the American Diabetes Association
    • 18 Nov 2015 Results assessing fracture risk (CANVAS (n = 4327) + pooled analysis of NCT01081834; NCT01064414; NCT01106625; NCT01106677; NCT00968812; NCT01106690; NCT01106651; NCT01137812 studies (n = 5867)) published in the Journal of Clinical Endocrinology and Metabolism.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top